Fig. 1

Inositide-Specific mutated variants in MDS patients at baseline, at the 4th cycle (T4) and at the 8th cycle (T8) of azacitidine and lenalidomide therapy. Venn diagram showing the global number of mutated variants in: a all patients analyzed, b Good Responders, c Transient Responders, d Non Responders